138 related articles for article (PubMed ID: 36884219)
1. Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Szczesniak R; Andrinopoulou ER; Su W; Afonso PM; Burgel PR; Cromwell E; Gecili E; Ghulam E; Goss CH; Mayer-Hamblett N; Keogh RH; Liou TG; Marshall B; Morgan WJ; Ostrenga JS; Pasta DJ; Stanojevic S; Wainwright C; Zhou GC; Fernandez G; Fink AK; Schechter MS
Ann Am Thorac Soc; 2023 Jul; 20(7):958-968. PubMed ID: 36884219
[No Abstract] [Full Text] [Related]
2. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis.
Konstan MW; VanDevanter DR; Sawicki GS; Pasta DJ; Foreman AJ; Neiman EA; Morgan WJ
Ann Am Thorac Soc; 2018 Apr; 15(4):485-493. PubMed ID: 29313709
[TBL] [Abstract][Full Text] [Related]
3. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
4. Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the U.S. Cystic Fibrosis Foundation Patient Registry.
Sears EH; Hinton AC; Lopez-Pintado S; Lary CW; Zuckerman JB
Ann Am Thorac Soc; 2023 Sep; 20(9):1250-1257. PubMed ID: 37027571
[No Abstract] [Full Text] [Related]
5. Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis.
Li D; Keogh R; Clancy JP; Szczesniak RD
Emerg Themes Epidemiol; 2017; 14():13. PubMed ID: 29201130
[TBL] [Abstract][Full Text] [Related]
6. Rapid lung function decline in adults with early-stage cystic fibrosis lung disease.
Dasenbrook EC; Fink AK; Schechter MS; Sanders DB; Millar SJ; Pasta DJ; Mayer-Hamblett N
J Cyst Fibros; 2020 Jul; 19(4):527-533. PubMed ID: 31870629
[TBL] [Abstract][Full Text] [Related]
7. Impact of loss to follow-up on survival estimation for cystic fibrosis.
Ostrenga JS; Whitney Brown A; Todd JV; Elbert A; Fink AK; Faro A; Marshall BC; Cromwell EA
Ann Epidemiol; 2023 Oct; 86():98-103.e5. PubMed ID: 37549758
[TBL] [Abstract][Full Text] [Related]
8. Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.
Szczesniak RD; Li D; Su W; Brokamp C; Pestian J; Seid M; Clancy JP
Am J Respir Crit Care Med; 2017 Aug; 196(4):471-478. PubMed ID: 28410569
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.
Wolter DJ; Onchiri FM; Emerson J; Precit MR; Lee M; McNamara S; Nay L; Blackledge M; Uluer A; Orenstein DM; Mann M; Hoover W; Gibson RL; Burns JL; Hoffman LR;
Lancet Respir Med; 2019 Dec; 7(12):1027-1038. PubMed ID: 31727592
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
11. Physical activity and exercise training in cystic fibrosis.
Radtke T; Smith S; Nevitt SJ; Hebestreit H; Kriemler S
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD002768. PubMed ID: 35943025
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
[TBL] [Abstract][Full Text] [Related]
13. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
14. A semiparametric approach to estimate rapid lung function decline in cystic fibrosis.
Szczesniak RD; McPhail GL; Duan LL; Macaluso M; Amin RS; Clancy JP
Ann Epidemiol; 2013 Dec; 23(12):771-7. PubMed ID: 24103586
[TBL] [Abstract][Full Text] [Related]
15. Reduced survival in adult cystic fibrosis despite attenuated lung function decline.
Keating C; Poor AD; Liu X; Chiuzan C; Backenroth D; Zhang Y; DiMango E
J Cyst Fibros; 2017 Jan; 16(1):78-84. PubMed ID: 27522311
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.
Cogen J; Emerson J; Sanders DB; Ren C; Schechter MS; Gibson RL; Morgan W; Rosenfeld M;
Pediatr Pulmonol; 2015 Aug; 50(8):763-70. PubMed ID: 26061914
[TBL] [Abstract][Full Text] [Related]
17. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.
Wells JM; Farris RF; Gosdin TA; Dransfield MT; Wood ME; Bell SC; Rowe SM
Lancet Respir Med; 2016 Aug; 4(8):636-645. PubMed ID: 27298019
[TBL] [Abstract][Full Text] [Related]
19. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001506. PubMed ID: 30260472
[TBL] [Abstract][Full Text] [Related]
20. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
